Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter November 15, 2013

Inoculation of the attenuated Coxsackievirus B3 Sabin3-like strain induces a protection against virulent CVB3 Nancy and CVB4 E2 strains in Swiss mice by both oral and intraperitoneal routes

  • Nadia Jrad-Battikh EMAIL logo , Amira Souii , Rym Hadhri , Mahjoub Aouni , Jawhar Gharbi and Manel M’hadheb-Gharbi
From the journal Biologia

Abstract

We have previously addressed the question of whether the attenuating mutations of domain V of the Poliovirus IRES were specific for a given genomic context or whether they could be extrapolated to a genomic related virus, the Coxsackievirus B3 (CVB3). Accordingly, we have described that Sabin3-like mutation (U473→C) introduced in the CVB3 genome led to a defective mutant with a serious reduction in translation efficiency. In this study, we assessed the protection provided by the Sabin3-like mutant against CVB3 infection. For this purpose, we analyzed, in vivo, the Sabin3-like phenotype in Swiss mice inoculated with CVB3 and CVB4 E2 prototype strains either by oral or intraperitoneal (i.p) routes and explored the capacity of this mutant to act as a vaccine vector after the challenge. The Sabin3-like RNA was detected by semi-nested PCR in different organs: heart, pancreas and intestine at 10 days post-inoculation with both oral and i.p routes. Additionally, we did not observe any histological alterations in heart and intestine tissues. RNA was detected in the different organs of all mice immunized with the Sabin3-like strain and challenged with either CVB3 or CVB4 E2 by oral route at 7 days post-challenge. In contrast, no histological alteration of heart or pancreas tissues was observed after challenge with both wild-strains. Interestingly, the detection of viral RNA in heart, pancreas and intestine of mice immunized by i.p route was negative at 7 days post-challenge with CVB3 and CVB4 E2, and mice were protected from myocarditis and pancreatitis.

[1] Bailey J.M. & Tapprich W.E. 2007. Structure of the 5’ nontranslated region of the coxsackievirus B3 genome: chemical modi-fication and comparative sequence analysis. J. Virol. 81: 650–668. http://dx.doi.org/10.1128/JVI.01327-0610.1128/JVI.01327-06Search in Google Scholar

[2] Ben M’hadheb-Gharbi M., Gharbi J., Paulous S., Brocard M., Komaromva A., Aouni M. & Kean K. 2006. Effects of the Sabin-like mutations in domain V of the internal ribosome entry segment on translational efficiency of Coxsackievirus B3. Mol. Genet. Genomics 276: 402–412. http://dx.doi.org/10.1007/s00438-006-0155-310.1007/s00438-006-0155-3Search in Google Scholar

[3] Ben M’hadheb-Gharbi M., Paulous S., Aouni M., Kean K.M. & Gharbi J. 2007. The substitution U475→C with Sabin3-like mutation within the IRES attenuate Coxsackievirus B3 cardiovirulence. Mol. Biotechnol. 36: 52–60. http://dx.doi.org/10.1007/s12033-007-0019-z10.1007/s12033-007-0019-zSearch in Google Scholar

[4] Bhattacharyya S. & Das S. 2005. Mapping of secondary structure of the spacer region within the 5′-untranslated region of the coxsackievirus B3 RNA: possible role of an apical GAGA loop in binding La protein and influencing internal initiation of translation. Virus Res. 108: 89–100. http://dx.doi.org/10.1016/j.virusres.2004.08.02010.1016/j.virusres.2004.08.020Search in Google Scholar

[5] Bopegamage S., Borsanyiova M., Vargova A., Petrovicova A., Benkovicova M. & Gomolcak P. 2003. Coxsackievirus infection of mice. I. Viral kinetics and histopathological changes in mice experimentally infected with coxsackieviruses B3 and B4 by oral route. Acta Virol. 47: 245–251. Search in Google Scholar

[6] Bopegamage S., Kovacova J., Vargova A., Motusova J., Petrovicova A., Bencovicova M., Gomolacak P., Bakkers J., Van Kuppeveld F., Melchers W.J.G. & Galama J.M. 2005. Coxsackie B virus infection of mice: inoculation by oral route protects the pancreas from damage, but not from infection. J. Gen. Virol. 86: 3271–3280. http://dx.doi.org/10.1099/vir.0.81249-010.1099/vir.0.81249-0Search in Google Scholar

[7] Chapman N.M., Ragland A., Smith L.J., Höfling K., Willian S., Semler B. & Tracy S. 2000. A group B Coxsackievirus/poliovirus 5’ nontranslated region chimera can act as an attenuated vaccine stain in mice. J. Virol. 74: 4047–4056. http://dx.doi.org/10.1128/JVI.74.9.4047-4056.200010.1128/JVI.74.9.4047-4056.2000Search in Google Scholar

[8] Chomczynski P. & Sacchi N. 1987. Single-step RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156–159. http://dx.doi.org/10.1016/0003-2697(87)90021-210.1016/0003-2697(87)90021-2Search in Google Scholar

[9] Dunn J.J., Chapman N.M., Tracy S. & Romero J.R. 2000. Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5’ nontranslated region. J. Virol. 74: 4787–4794. http://dx.doi.org/10.1128/JVI.74.10.4787-4794.200010.1128/jvi.74.10.4787-4794.2000Search in Google Scholar

[10] Fohlman J., Ilbäck N.G., Friman G. & Morein B. 1990. Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 8: 381–384. http://dx.doi.org/10.1016/0264-410X(90)90098-710.1016/0264-410X(90)90098-7Search in Google Scholar

[11] Godney E.K., Arizpe H.M. & Gaunti C.J. 1988. Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis. Viral Immunol. 1: 305–314. http://dx.doi.org/10.1089/vim.1987.1.30510.1089/vim.1987.1.305Search in Google Scholar PubMed

[12] Henke A., Jarasch N., Martin U., Wegert J., Wildner A., Zell R. & Wutzler P. 2008. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease. Int. J. Med. Microbiol. 298: 127–134. http://dx.doi.org/10.1016/j.ijmm.2007.08.01010.1016/j.ijmm.2007.08.010Search in Google Scholar

[13] Henke A., Zell R. & Stelzner A. 2001. DNA vaccine-mediated immune responses in Coxsackievirus B3-infected mice. Antiviral Res. 49: 49–54. http://dx.doi.org/10.1016/S0166-3542(00)00132-710.1016/S0166-3542(00)00132-7Search in Google Scholar

[14] Huber S. & Ramsingh A.I. 2004. Coxsackievirus-induced pancreatitis. Viral Immunol. 17: 358–369. http://dx.doi.org/10.1089/vim.2004.17.35810.1089/vim.2004.17.358Search in Google Scholar PubMed

[15] Jackson R.J. & Kaminski A. 1995. Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. RNA 1: 985–1000. Search in Google Scholar

[16] Jaidane H., Gharbi J., Lobert P.E., Lucas B., Hiar R., Ben M’hadheb M., Brilot F., Geenen V., Aouni M. & Hober D. 2006. Prolonged viral RNA detection in blood and lymphoid tissues from Coxsackievirus B4E2 orally-inoculated Swiss mice. Microbiol. Immunol. 50: 971–974. 10.1111/j.1348-0421.2006.tb03874.xSearch in Google Scholar PubMed

[17] Kawai C. 1999. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99: 1091–1100. http://dx.doi.org/10.1161/01.CIR.99.8.109110.1161/01.CIR.99.8.1091Search in Google Scholar PubMed

[18] Kim D.S., Cho Y.J., Kim B.G., Lee S.H. & Nam J.H. 2009. Systematic analysis of attenuated Coxsackievirus expressing a foreign gene as a viral vaccine vector. Vaccine 28: 1234–1240. http://dx.doi.org/10.1016/j.vaccine.2009.11.01710.1016/j.vaccine.2009.11.017Search in Google Scholar PubMed

[19] Kim J.Y., Jeon E.S., Lim B.K., Kim S.M., Chung S.K. & Kim J.M. 2005. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 23: 1672–1679. http://dx.doi.org/10.1016/j.vaccine.2004.10.00810.1016/j.vaccine.2004.10.008Search in Google Scholar PubMed

[20] Klingel K., Hohenadl C., Canu A., Albrecht M., Seemannn M., Mall G. & Kandolf R. 1992. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection, quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl. Acad. Sci. USA 89: 314–318. http://dx.doi.org/10.1073/pnas.89.1.31410.1073/pnas.89.1.314Search in Google Scholar PubMed PubMed Central

[21] Knowlton K.U., Jeon E.S., Berkley N., Wessely R. & Huber S. 1996. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of theWoodruff variant of coxsackievirus B3. J. Virol. 70: 7811–7818. 10.1128/jvi.70.11.7811-7818.1996Search in Google Scholar PubMed PubMed Central

[22] Kong Q., Richter L., Yang Y.F., Arntzen C.J., Mason H.S. & Thanavala Y. 2001. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA 98: 11539–11544. http://dx.doi.org/10.1073/pnas.19161759810.1073/pnas.191617598Search in Google Scholar PubMed PubMed Central

[23] La Monica N. & Racaniello V.R. 1989. Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y. J. Virol. 63: 2357–2560. 10.1128/jvi.63.5.2357-2360.1989Search in Google Scholar

[24] Landau B.J., Whittier P.S., Finkelstein S.D., Alstein B., Grun J.B. & Schultz M. 1990. Induction of heterotypic virus resistance in adult inbred mice immunized with a variant of Coxsackievirus B3. Microb. Pathog. 8: 289–298. http://dx.doi.org/10.1016/0882-4010(90)90054-T10.1016/0882-4010(90)90054-TSearch in Google Scholar

[25] Leparc I., Fuchs F., Kopecka H. & Aymard M. 1993. Use of polymerase chain reaction with a murine model of picornavirusinduced myocarditis. J. Clin. Microbiol. 31: 2890–2894. 10.1128/jcm.31.11.2890-2894.1993Search in Google Scholar

[26] Lim B.K., Shin J.O., Lee S.C., Kim D.K., Choi D.J. & Choe S.C. 2005. Long-term cardiac gene expression using a coxsackieviral vector. J. Mol. Cell. Cardiol. 38: 745–751. http://dx.doi.org/10.1016/j.yjmcc.2005.02.01810.1016/j.yjmcc.2005.02.018Search in Google Scholar

[27] Maisch B., Ristic A.D., Hufnagel G. & Pankuweit S. 2002. Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc. Pathol. 11: 112–122. http://dx.doi.org/10.1016/S1054-8807(01)00113-210.1016/S1054-8807(01)00113-2Search in Google Scholar

[28] Malnou C.E., Pöyry T.A., Jackson R.J. & Kean K.M. 2002. Poliovirus internal ribosome entry segment structure alterations that specifically affect function in neuronal cells: molecular genetic analysis. J. Virol. 76: 10617–10626. http://dx.doi.org/10.1128/JVI.76.21.10617-10626.200210.1128/JVI.76.21.10617-10626.2002Search in Google Scholar

[29] Mason H.S., Warzecha H., Mor T. & Arntzen C.J. 2002. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol. Med. 8: 324–329. http://dx.doi.org/10.1016/S1471-4914(02)02360-210.1016/S1471-4914(02)02360-2Search in Google Scholar

[30] Ouyang X., Zhang H., Trevor A.B. & Archard L.C. 1995. Detection of Coxsackievirus B3 RNA in mouse myocarditis by nested polymerase chain reaction. Clin. Diagn. Virol. 3: 233–245. http://dx.doi.org/10.1016/S0928-0197(94)00040-910.1016/S0928-0197(94)00040-9Search in Google Scholar

[31] Reed L.J. & Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27: 493–497. 10.1093/oxfordjournals.aje.a118408Search in Google Scholar

[32] Sabin A.B. 1985. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 151: 420–436. http://dx.doi.org/10.1093/infdis/151.3.42010.1093/infdis/151.3.420Search in Google Scholar PubMed

[33] Sabin A.B. 1995. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA 194: 872–876. http://dx.doi.org/10.1001/jama.1965.0309021003601010.1001/jama.1965.03090210036010Search in Google Scholar

[34] Slifka M.K., Pagarigan R., Mena I., Feuer R. & Whitton J.L. 2001. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J. Virol. 75: 2377–2387. http://dx.doi.org/10.1128/JVI.75.5.2377-2387.200110.1128/JVI.75.5.2377-2387.2001Search in Google Scholar

[35] Souii A., Ben M’hadheb-Gharbi M., Sargueil B., Brossard A., Chamond N., Aouni M. & Gharbi J. 2013. Ribosomal initiation complex assembly within the wild-strain of Coxsackievirus B3 and live-attenuated Sabin3-like IRESes during the initiation of translation. Int. J. Mol. Sci. 14: 4400–4418. http://dx.doi.org/10.3390/ijms1403440010.3390/ijms14034400Search in Google Scholar

[36] Svitkin Y.V., Cammack, N., Minor P.D. & Almon J.W. 1990. Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472-U. Virology 175: 103–109. http://dx.doi.org/10.1016/0042-6822(90)90190-310.1016/0042-6822(90)90190-3Search in Google Scholar

[37] Tam P.E. 2006. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol. 19: 133–146. http://dx.doi.org/10.1089/vim.2006.19.13310.1089/vim.2006.19.133Search in Google Scholar PubMed

[38] Tracy S., Chapman N.M. & Tu Z. 1992. Coxsackievirus B3 from an infectious cDNA copy of the genome is cardiovirulent in mice. Arch. Virol. 122: 399–409. http://dx.doi.org/10.1007/BF0131720210.1007/BF01317202Search in Google Scholar PubMed

[39] Tu Z., Chapman N.M., Hufnagel G., Tracy S., Romero J.R., Barry W.H., Zhao L., Currey K. & Shapiro B. 1995. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5’ nontranslated region. J. Virol. 69: 4607–4618. 10.1128/jvi.69.8.4607-4618.1995Search in Google Scholar PubMed PubMed Central

[40] Yoon J.W., Austin M., Onodera T. & Notkins A.L. 1979. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. New Engl. J. Med. 300: 1173–1179. http://dx.doi.org/10.1056/NEJM19790524300210210.1056/NEJM197905243002102Search in Google Scholar PubMed

[41] Zhang H., Morgan-Capner P., Latif N., Pandolfino Y.A., Fan W. & Dunn M.J. 1997. Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain. Am. J. Pathol. 150: 2197–2207. Search in Google Scholar

Published Online: 2013-11-15
Published in Print: 2014-1-1

© 2013 Slovak Academy of Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.2478/s11756-013-0292-1/html
Scroll to top button